Ferroptosis Regulator Information

General Information of the Ferroptosis Regulator (ID: REG30047)
Regulator Name LINC00618 (IncRNA)
Synonyms
LINC00618
    Click to Show/Hide
Gene Name LINC00618
Gene ID 145249
Regulator Type lncRNA
Ensembl ID .
HGNC ID
HGNC:20110
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
LINC00618 can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Cystine/glutamate transporter (SLC7A11) [Driver; Suppressor]
 Target Info 
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Target for Ferroptosis Suppressor
Responsed Disease Myeloid leukaemia ICD-11: 2B33
 Disease Info 
Responsed Drug Vincristine Investigative
 Drug Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model
 HL-60 cells Adult acute myeloid leukemia Homo sapiens CVCL_0002
K-562 cells Chronic myelogenous leukemia Homo sapiens CVCL_0004
Response regulation LINC00618, is reduced in human leukemia and strongly increased by vincristine (VCR) treatment. Furthermore, LINC00618 promotes apoptosis by increasing the levels of BCL2-Associated X (BAX) and cleavage of caspase-3. LINC00618 also accelerates ferroptosis by increasing the levels of lipid reactive oxygen species (ROS) and iron, two surrogate markers of ferroptosis, and decreasing the expression of solute carrier family 7 member 11 (SLC7A11).
Myeloid leukaemia [ICD-11: 2B33]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator LINC00618 (IncRNA) lncRNA
 Regulator Info 
Responsed Drug Vincristine Investigative
 Drug Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model
 HL-60 cells Adult acute myeloid leukemia Homo sapiens CVCL_0002
K-562 cells Chronic myelogenous leukemia Homo sapiens CVCL_0004
Response regulation LINC00618, is reduced in human leukemia and strongly increased by vincristine (VCR) treatment. Furthermore, LINC00618 promotes apoptosis by increasing the levels of BCL2-Associated X (BAX) and cleavage of caspase-3. LINC00618 also accelerates ferroptosis by increasing the levels of lipid reactive oxygen species (ROS) and iron, two surrogate markers of ferroptosis, and decreasing the expression of solute carrier family 7 member 11 (SLC7A11).
Vincristine [Investigative]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the Ferroptosis-centered Drug Response [1]
Drug for Ferroptosis Inducer
Response Target Cystine/glutamate transporter (SLC7A11) Driver; Suppressor
 Target Info 
Responsed Disease Myeloid leukaemia ICD-11: 2B33
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model
 HL-60 cells Adult acute myeloid leukemia Homo sapiens CVCL_0002
K-562 cells Chronic myelogenous leukemia Homo sapiens CVCL_0004
Response regulation LINC00618, is reduced in human leukemia and strongly increased by vincristine (VCR) treatment. Furthermore, LINC00618 promotes apoptosis by increasing the levels of BCL2-Associated X (BAX) and cleavage of caspase-3. LINC00618 also accelerates ferroptosis by increasing the levels of lipid reactive oxygen species (ROS) and iron, two surrogate markers of ferroptosis, and decreasing the expression of solute carrier family 7 member 11 (SLC7A11).
References
Ref 1 A Nuclear Long Non-Coding RNA LINC00618 Accelerates Ferroptosis in a Manner Dependent upon Apoptosis. Mol Ther. 2021 Jan 6;29(1):263-274. doi: 10.1016/j.ymthe.2020.09.024. Epub 2020 Sep 20.